DLL4 Protein & Antibody

Delta-Like 4

DLL4 Products

DLL4 Protein, Recombinant

Molecule	Species	Description	Cat. No
DLL4/Delta4	Human	DLL4/Delta4/Fc Protein, Recombinant	10171-H02H
DLL4/Delta4	Human	DLL4/Delta4 Protein, Recombinant	10171-H08H
DLL4/Delta4	Mouse	DLL4/Delta4 Protein, Recombinant	50640-M08H

  10171-H08H:  Measured by its ability to bind human Notch1 in a functional ELISA.

DLL4 Antibody

Molecule	Application	Description	Cat. No
Human DLL4/Delta4	ELISA	DLL4/Delta4 Antibody, Mouse MAb	10171-MM06
Human	WB, ELISA	DLL4/Delta4 Antibody, Rabbit MAb	10171-R003
Human DLL4/Delta4	WB, ELISA	Rabbit Polyclonal Antibody	10171-RP01
Human DLL4/Delta4	WB, ELISA	Rabbit Polyclonal Antibody (Antigen Affinity Purified)	10171-RP02
Mosue DLL4/Delta4	WB, ELISA	DLL4/Delta4 Antibody, Rabbit MAb	50640-R006
Mosue DLL4/Delta4	WB, ELISA	DLL4/Delta4 Antibody, Rabbit PAb	50640-RP01
Mosue DLL4/Delta4	WB, ELISA	DLL4/Delta4 Antibody, Rabbit PAb (Antigen Affinity Purified)	50640-RP02

DLL4 Elisa Pair Set

Molecule	Application	Description	Cat. No
Mosue DLL4/Delta4	ELISA	DLL4 Elisa Pair Set	SEK50640

DLL4 cDNA Clone

Molecule	Species	Description	Cat. No
DLL4/Delta4	Human	Homo sapiens DLL4/Delta4 cDNA Clone(NM_01974.2)	HG10171-M
DLL4/Delta4	Mouse	Mus musculus DLL4/Delta4 cDNA Clone	MG50640-M

DLL4 Related Areas

Signal Transduction>>Notch Signaling Pathway>>DLL4/Delta4

Stem Cell>>Notch Signaling Pathway>>DLL4/Delta4

DLL4 Alternative Names

DLL4, delta 4, MGC126344, hdelta2, delta ligand 4 [Homo sapiens]

Dll4, Delta4, RP23-46P4.8 [Mus musculus]

DLL4 Background

Delta-like protein 4 (DLL4, Delta4), a type I membrane-bound Notch ligand, is one of five known Notch ligands in mammals and interacts predominantly with Notch 1, which has a key role in vascular development. Recent studies yield substantial insights into the role of DLL4 in angiogenesis. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a 'brake' on VEGF-induced vessel growth, forming an autoregulatory negative feedback loop inactivating VEGF. DLL4 is downstream of VEGF signaling and its activation triggers a negative feedback that restrains the effects of VEGF. Attenuation of DLL4/Notch signaling results in chaotic vascular network with excessive branching and sprouting. DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore, the molecule is internalized on binding its receptor and often transported to the nucleus. In pathological conditions, such as cancer, DLL4 is up-regulated strongly in the tumour vasculature. Blockade of DLL4-mediated Notch signaling strikingly increases nonproductive angiogenesis, but significantly inhibits tumor growth in preclinical mouse models. In preclinical studies, blocking of DLL4/Notch signaling is associated with a paradoxical increase in tumor vessel density, yet causes marked growth inhibition due to functionally defective vasculature. Thus, DLL4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy.

DLL4 Related Studies

1. Yan M, et al. (2007) Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res. 13(24): 7243-6.
2. Sainson RC, et al. (2007) Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Trends Mol Med. 13(9): 389-95.
3. Martinez JC, et al. (2009) Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues. Histopathology. 54(5): 598-606.
4. Li JL, et al. (2010) Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. Future Oncol. 6(7): 1099-103.